Study identifier:D2452L00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multicenter, non-comparative, phase IV study to evaluate the effect of candesartan based therapy in the percent change of proBNP level after 24 week treatment in the patients with hypertension with left ventricular hypertrophy
hypertension
Phase 4
No
Candesartan, Felodipine
All
315
Interventional
18 Years - 75 Years
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Candesartan Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures. | Drug: Candesartan 16 mg once daily in oral tablet form Other Name: Atacand Drug: Candesartan 32 mg once daily in oral tablet form Other Name: Antacand Drug: Felodipine 5 mg once daily in oral tablet form Drug: Felodipine 10 mg once daily in oral tablet form |